-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, ExejzPLFWPqDMgaPmyFgZAcBzSqVmNIKV21VPnv0U9WdbNIoxKA8avlfaNrWqSy0 JLUkSRrbCEW6mo1V4JvkFQ== 0001016193-08-000032.txt : 20080624 0001016193-08-000032.hdr.sgml : 20080624 20080624151201 ACCESSION NUMBER: 0001016193-08-000032 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20080624 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20080624 DATE AS OF CHANGE: 20080624 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIO-PATH HOLDINGS INC CENTRAL INDEX KEY: 0001133818 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-MISCELLANEOUS SHOPPING GOODS STORES [5940] IRS NUMBER: 870652870 STATE OF INCORPORATION: UT FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-105075 FILM NUMBER: 08914169 BUSINESS ADDRESS: STREET 1: 3293 HARRISON BOULEVARD STE 230 CITY: OGDEN STATE: UT ZIP: 84403 BUSINESS PHONE: 8013995500 MAIL ADDRESS: STREET 1: 3293 HARRISON BOULEVARD STE 230 CITY: OGDEN STATE: UT ZIP: 84403 FORMER COMPANY: FORMER CONFORMED NAME: OGDEN GOLF CO CORP DATE OF NAME CHANGE: 20010205 8-K 1 fm8k-0608.htm BIO-PATH HOLDINGS, INC. FORM 8-K fm8k-0608.htm
 
 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549


FORM 8-K


CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934


Date of report (Date of earliest event reported)    June 24, 2008

BIO-PATH HOLDINGS, INC.
(Exact Name of Registrant as Specified in Its Charter)

Utah
(State or Other Jurisdiction of Incorporation)

333-105075
87-0652870
(Commission File Number)
(IRS Employer Identification No.)
   
3293 Harrison Blvd., Ste. 230, Ogden, UT
84403
(Address of Principal Executive Offices)
(Zip Code)

801-399-5500
(Registrant’s Telephone Number, Including Area Code)


(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨                 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨                 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨                 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨                 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 
 

 Item 8.01 Other Events

On June 24, 2008, Bio-Path Holdings, Inc., announced that Hans A. de Haan, M.D., Ph.D., F.F.P.M., F.R.C.S., has joined Bio-Path as its Medical Officer. The press release relating to this announcement is attached hereto as an exhibit and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits

 Exhibits

 
Exhibit Number
Description
  
       
 
99.1
Press Release
  

SIGNATURES

Pursuant to the requirements of the Securities Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated:  June 24, 2008
BIO-PATH HOLDINGS INC.
   
 
By:  /s/ Peter Nielsen
 
Chief Executive Officer












 

 
2
 

EX-99.1 2 ex99-1.htm PRESS RELEASE ex99-1.htm

 
 
 

Exhibit 99.1
Form 8-K/A
Bio-Path Holdings, Inc.
File No. 333-105075


Bio-Path Holdings, Inc.


Bio-Path Holdings, Inc. Announces Dr. Hans A. de Haan Has Joined The Company As Medical Officer


FOR IMMEDIATE RELEASE


June 23, 2008 HOUSTON, TX – Bio-Path Holdings, Inc., a publicly traded biotechnology company with drug development operations in Houston, Texas (symbol BPTH), announced today that Hans A. de Haan, M.D., Ph.D., F.F.P.M., F.R.C.S., has joined Bio-Path as its Medical Officer.  Dr. de Haan will be the principal interface for the conduct of the Company’s upcoming Phase 1 clinical study of liposomal Grb-2 in chronic myelogenous leukemia (CML), conducted at The University of Texas M. D. Anderson Cancer Center (“M. D. Anderson”).

Dr. de Haan has extensive domestic and international experience in the pharmaceutical industry, but especially in clinical development and regulatory affairs.  Over the past decade he has provided consulting services for numerous pharmaceutical companies, most recently to Pharmion Corp., a biotech company that was acquired by Celgene Corp. in March 2008. Prior entities included one of the leading developers of single nucleic acid (antisense), a technology that Bio-Path is enhancing with its proprietary delivery technology.  Dr. de Haan also served as an adjunct professor at the San Diego University for Integrative Studies.  Dr. de Haan was educated in medicine and surgery in the United Kingdom at King’s College, London, and is both a Fellow of the Faculty of Pharmaceutical Medicine and of the Royal College of Surgeons (UK).  He is a past President and Chairman of the Board of the American Academy of Pharmaceutical Physicians.

Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings, Inc. commented on Dr. de Haan, “We are very fortunate to have Hans join the Bio-Path team as its medical officer, signaling the entry of our lead compound into human studies and proof of concept.  We shall now build the capability to take multiple candidates simultaneously into full clinical development.  Hans’s broad experience as a medical researcher and pharmaceutical physician brings tremendous strength to Bio-Path’s organization.  Dr. de Haan reflected, “Antisense and siRNA are showing great potential for the treatment of cancer and many other serious diseases but effective drug delivery remains a significant challenge. Bio-Path’s liposomal delivery technology offers a promising solution and I feel privileged to work with Peter and M. D. Anderson, in the expectation of bringing Bio-Path’s technology to the marketplace within the foreseeable future.”


 
 
 

About Bio-Path Holdings, Inc.

Bio-Path is developing leading edge, patented, liposomal drug delivery systems with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug undergoing final pre-clinical development.  Bio-Path’s drug delivery technology distributes nucleic acid drugs systemically, throughout the human body, via simple intravenous infusion. The delivery technology can be applied both to double stranded (siRNA) and single stranded (antisense) nucleic acid compounds with the potential to revolutionize the treatment of cancer and other diseases where drugable targets of disease are well characterized.

About M. D. Anderson Cancer Center
 
The University of Texas M. D. Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. M. D. Anderson is one of only 39 Comprehensive Cancer Centers designated by the National Cancer Institute. For five of the past eight years, M. D. Anderson has ranked No. 1 in cancer care in "America's Best Hospitals," a survey published annually in U.S. News and World Report.
 
 
Safe Harbor Statement: All statements in this news release, not statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward- looking statements.
 
Contact Information:

Internal Public Relations:
Douglas P. Morris, VP Corporate Development
Tel 801.580.2326






 

 
2
 

-----END PRIVACY-ENHANCED MESSAGE-----